Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with both Chronic Hepatitis B and HIV
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Thomas Campbell, MD
Study ID
Protocol Number: 22-2156
More information available at ClinicalTrials.gov: NCT05551273
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers